FDA Noxafil Approval Delayed By Last-Minute Label, Data Integrity Issues
Executive Summary
FDA overshot the user fee goal on Schering-Plough's Noxafil (posaconazole) to address labeling and data integrity issues that arose late in the review of the antifungal, FDA review documents indicate